HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

NIH Makes Research Funding Data More “Transparent” To Public

This article was originally published in The Tan Sheet

Executive Summary

The National Institutes of Health is targeting the summer of 2008 for the launch of an improved system for reporting its funding levels for various research and disease categories, the agency said during an advisory council meeting in Rockville, Md. Sept. 5

You may also be interested in...



Capitol Hill In Brief

Harkin on NIH funding: Sen. Tom Harkin, D-Iowa, said at a March 19 appropriations subcommittee hearing he and ranking minority member Arlen Specter, R-Pa., will not allow proposed cuts in NIH funding. President Bush's proposed fiscal 2008 budget would cut NIH spending by $328 mil., but Harkin said the actual reduction will be about $529 mil. because NIH has to "pick up the entire tab for the global AIDS fund rather than sharing it with the State Department." Specter said with a federal budget of $2.9 tril., an allocation of less than $30 bil. to NIH is "scandalous." NIH Director Elias A. Zerhouni, M.D. said the cut would force the institute to reduce its number of clinical trials because they are "extremely expensive." Harkin said the subcommittee will hear from the directors of all NIH centers and institutes later this spring...

P&G Restores Volume Growth In Beauty, Grooming After Pricing Run

Procter & Gamble reports strong consumer spending in the US and Europe after a 3% increase in product pricing over the past year. Dragging on fiscal third-quarter results, sales of SK-II in China fell 30% for the January-March period, while lower incidence of cough and cold impacted Health Care performance.

MoCRA’s Adulteration Ambiguity And FDA’s New Cosmetic Recall Authority: Attorney Weighs In

The US FDA should use guidance or rulemaking to clarify MoCRA provisions related to adulteration, Amin Wasserman Gurnani attorney Angela Diesch suggested at the Independent Beauty Association’s Cosmetics Convergence Spring Symposium. Attendees also sought her take on whether the agency’s new recall authority is likely to spell an increase in cosmetic product recalls.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

RS137872

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel